IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 93.22

Change

+0.91 (+0.99)%

Market Cap

N/A

Volume

0.36M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-25 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.27 (+0.86%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

+0.32 (+0.46%)

USD 2.77B
FXH First Trust Health Care AlphaD..

+0.39 (+0.35%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-0.56 (-0.62%)

USD 0.20B
IDNA iShares Genomics Immunology an..

-0.18 (-0.79%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.81 (-2.55%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.41 (+0.42%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.25 (-0.84%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-1.01 (-1.61%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.54 (-2.58%)

USD 6.67M

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.97 % 0.00 %

+1.38 (+0.96%)

USD 1.45B
XHC:CA iShares Global Healthcare.. 99.94 % 0.65 %

+0.58 (+0.96%)

CAD 0.56B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.43% 86% B+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.43% 86% B+ 86% B+
Trailing 12 Months  
Capital Gain 1.17% 57% F 38% F
Dividend Return 1.40% 94% A 24% F
Total Return 2.57% 57% F 29% F
Trailing 5 Years  
Capital Gain 45.59% 62% D 65% D
Dividend Return 8.54% 79% B- 22% F
Total Return 54.13% 71% C- 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 5.38% 67% D+ 51% F
Dividend Return 6.34% 71% C- 47% F
Total Return 0.96% 74% C 23% F
Risk Return Profile  
Volatility (Standard Deviation) 13.17% 76% C+ 71% C-
Risk Adjusted Return 48.15% 81% B- 61% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike